AVXL PEER ANALYSIS

Anavex Life Sciences Corp — metric-by-metric comparison with peers and the industry median

AVXLAnavex Life Sciences Corp

🇺🇸 USA · NASDAQ · Healthcare · Biotechnology

Value itDuel

Overall Profile & Returns

· Biotechnology

Position Within Industry

0 = weak quartile, 100 = strong quartile
ValuationProfitabilityFinancial Health
AVXLIndustry median

Scores normalize each metric against industry quartiles (p25–p75); direction is inverted for lower-is-better metrics.

Return Comparison

1-Year
Split-adjusted
AVXL-73.9%MSB+27.6%RTALB+24.1%TLX-29.5%
Year-to-Date (YTD)
AVXL-22.5%MSB-24.3%RTALB+5.0%TLX+50.7%

Key Metric Comparison

P/E

Lower is better
AVXLMSBRTALB4.89TLXMedian 17.91

ROE

Higher is better
AVXL-33.6%MSB-11.3%RTALB15.1%TLX-1.8%Median -47.5%

Net Margin

Higher is better
AVXLMSB-115.3%RTALB136.3%TLX-0.9%Median -125.7%

Revenue Growth

Higher is better
AVXLMSB410.4%RTALB24.0%TLX56.3%Median 5.1%

All Metrics

Valuation
MetricAVXLMSBRTALBTLXInd. Median
P/E4.8917.91
P/B1.940.616.373.51
EV/EBITDA74.61120.1414.82
P/S31.616.673.2410.89
Financial Health
MetricAVXLMSBRTALBTLXInd. Median
Current Ratio20.871.211.435.90
Debt/Equity1.2%112.3%10.9%
NetDebt/EBITDA0.9013.131.15
Profitability
MetricAVXLMSBRTALBTLXInd. Median
Net Margin-115.3%136.3%-0.9%-125.7%
ROE-33.6%-11.3%15.1%-1.8%-47.5%
ROA-31.1%-8.6%13.1%-0.7%-35.8%
EBITDA Margin-76.6%9.0%3.0%-105.8%
Growth + Dividend
MetricAVXLMSBRTALBTLXInd. Median
Rev. Growth410.4%24.0%56.3%5.1%
NI Growth134.0%12.1%
Div. Yield0.0%0.0%0.2%
Payout0.0%0.0%0.0%

The green dot marks the best value in the group given the metric direction (higher/lower is better). All metrics use trailing-twelve-month (TTM) data.

Go deeper on AVXL

Data on this page refreshes once per day. Price data as of Jul 2, 26. This content is for informational purposes only and is not investment advice.